19 March 2019
JUVE Nachricht vom 19.03.2019 - Generics manufacturers prevail over Hogan Lovells client MSD
Various generics manufacturers have won in the second instance in the dispute over supplementary protection certificates for cholesterol-lowering drug Inegy. The Higher Regional Court Düsseldorf dismissed the appeal of US originator Merck Sharp Dome (MSD) (case IDs: I-2 U 58/18 - I-2 U 64/18 and I-2 U 82/18). The various pharmaceutical companies may continue to market imitation products in Germany, using the active substance combination ezitimibe and simvastatin.
Read the whole article Generics manufacturers prevail over Hogan Lovells client MSD.
Related Insights
Life sciences & healthcare
Click here to find out more
Early IP Strategy for Life Sciences Start-Ups Pays off
We explain the 5 biggest pitfalls
22 March 2024
Briefing
UPC
Click here to find out more
Outlook on 2024 – Which is the current standard for the validity of the patent for getting a preliminary injunction in the German Courts and the UPC?
18 December 2023
In-depth analysis
UPC
Click here to find out more
The first 100 days of the UPC from a life sciences perspective – a very good message
20 September 2023
Quick read
by Dr. Anja Lunze, LL.M. and Dr. Nora E. Wessendorf, LL.M. (Washington)